within Pharmacolibrary.Drugs.ATC.B;

model B01AE02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0026,
    adminDuration  = 600,
    adminMass      = 0.15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0067,
    k12             = 220,
    k21             = 220
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AE02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lepirudin is a recombinant hirudin derived from yeast cells and is a direct thrombin inhibitor. It was used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT). Due to risk of serious bleeding and the availability of alternative agents, lepirudin was withdrawn from the market and is no longer approved for use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as observed in adult patients with heparin-induced thrombocytopenia, following intravenous administration.</p><h4>References</h4><ol><li><p>Meiring, SM, et al., &amp; Kotzé, HF (1999). Sites of elimination and pharmacokinetics of recombinant [131I]lepirudin in baboons. <i>Journal of pharmaceutical sciences</i> 88(5) 523–529. DOI:<a href=&quot;https://doi.org/10.1021/js980407q&quot;>10.1021/js980407q</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10229643/&quot;>https://pubmed.ncbi.nlm.nih.gov/10229643</a></p></li><li><p>Fries, D (2011). Thrombosis prophylaxis in critically ill patients. <i>Wiener medizinische Wochenschrift (1946)</i> 161(3-4) 68–72. DOI:<a href=&quot;https://doi.org/10.1007/s10354-011-0878-6&quot;>10.1007/s10354-011-0878-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21404142/&quot;>https://pubmed.ncbi.nlm.nih.gov/21404142</a></p></li><li><p>Baetz, BE, &amp; Spinler, SA (2008). Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. <i>Pharmacotherapy</i> 28(11) 1354–1373. DOI:<a href=&quot;https://doi.org/10.1592/phco.28.11.1354&quot;>10.1592/phco.28.11.1354</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18956996/&quot;>https://pubmed.ncbi.nlm.nih.gov/18956996</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AE02;
